Combination of Nivolumab and DHAP in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (Nivo-DHAP)

Condition:   Hodgkin Lymphoma Intervention:   Drug: Nivolumab Sponsor:   State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials